Radiopharmaceutical · Acts on carbonic anhydrase IX (CA9) · developed by Telix Pharmaceuticals Pty
Zirconium Zr 89 girentuximab is a radioimmunoconjugate comprising a chimeric monoclonal antibody labeled with zirconium-89 for positron emission tomography imaging. The antibody binds carbonic anhydrase IX (CAIX), a hypoxia-inducible transmembrane protein overexpressed on renal cell carcinoma and other tumors. It enables imaging and quantification of CAIX-expressing tumor cells.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT06750419 | Phase 3 | Clear Cell Renal Cell Carcinoma | Recruiting | TLX |
| NCT07077083 | Phase 2 | Clear Cell Renal Cell Carcinoma (ccRCC) | Not yet recruiting | TLX |
| NCT06447103 | Phase 2 | Clear Cell Renal Cell Carcinoma | Recruiting | TLX |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
ccRCCClear Cell Renal Cell CarcinomaClear Cell Renal Cell Carcinoma (ccRCC)Sarcomatoid Renal Cell CarcinomaStage II Renal Cell CancerStage III Renal Cell CancerStage IV Renal Cell Cancer
Updated Oct 3, 2026. Something wrong or missing? Report it on the TLX page.
See TLX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
TLX catalysts and pipeline →